Zoetis Inc (ZTS)
194.81
-0.06
(-0.03%)
USD |
NYSE |
Sep 27, 16:00
194.91
+0.10
(+0.05%)
After-Hours: 20:00
Zoetis Research and Development Expense (Annual): 614.00M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 614.00M |
| December 31, 2022 | 539.00M |
| December 31, 2021 | 508.00M |
| December 31, 2020 | 463.00M |
| December 31, 2019 | 457.00M |
| December 31, 2018 | 432.00M |
| December 31, 2017 | 382.00M |
| December 31, 2016 | 376.00M |
| Date | Value |
|---|---|
| December 31, 2015 | 364.00M |
| December 31, 2014 | 396.00M |
| December 31, 2013 | 399.00M |
| December 31, 2012 | 409.00M |
| December 31, 2011 | 427.00M |
| December 31, 2010 | 411.00M |
| December 31, 2009 | 368.00M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
457.00M
Minimum
2019
614.00M
Maximum
2023
516.20M
Average
508.00M
Median
2021
Research and Development Expense (Annual) Benchmarks
| Pfizer Inc | 10.68B |
| Alnylam Pharmaceuticals Inc | 1.004B |
| Biomarin Pharmaceutical Inc | 746.77M |
| Corcept Therapeutics Inc | 184.35M |
| Ionis Pharmaceuticals Inc | 899.62M |